WHO and UN actions undermine IP and hurt innovation, warns PhRMA
18-03-2019
PhRMA urges USTR to protect US innovation abroad
13-02-2017
BIO welcomes ‘Special 301 Report’
29-04-2016
golden_brown / iStockphoto.com
Trade associations Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Innovation Organization (BIO) have called for Malaysia to be placed on the US Trade Representative’s (USTR) watch list in its “2018 Special 301 Report”.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
PhRMA, BIO, USTR, innovation, patent, Special 301 Report, medicines, IP protection, market access, barriers, biopharmaceuticals
